Detalhe da pesquisa
1.
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Gynecol Oncol
; 178: 161-169, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890345
2.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32656799
3.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499244
4.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30559051
5.
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Clin Ther
; 46(3): 228-238, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423866
6.
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial.
Leukemia
; 34(2): 604-612, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31611625
7.
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol
; 6(12): e616-e629, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31624047
8.
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Trials
; 19(1): 169, 2018 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29514706